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Are All End
Points Created Equal?
The Case for Weighting*
Robert F. Wilson, MD, Alan K. Berger, MD
Minneapolis, Minnesota
The goal of coronary revascularization, indeed of all medical
treatments, is to improve outcomes for patients, but what
does “improve outcomes” mean? Usually, there are many
outcomes to a treatment, relief of symptoms, reduced risk of
death and disability, major complications, minor nuisances,
financial impact, pain, recovery time, and so on. How do we
weigh these different aspects of outcome to determine which
treatment is preferred?
See page 538
The study by Boudriot et al. (1) in this issue of the Journal
llustrates the problem of weighing the impact of one aspect
f outcome against another. The authors compared the
utcomes of coronary artery bypass grafting (CABG) sur-
ery to that of percutaneous coronary intervention (PCI)
ith sirolimus-eluting stents for the treatment of unpro-
ected left main coronary artery (LMCA) stenosis. In a
andomized trial involving 201 patients, they found 1-year
ortality was about the same with both methods, and
erioperative complications were markedly higher among
atients undergoing CABG (30% vs. 4%). There was no
ignificant difference between the treatment arms with
espect to angina relief at 1 year (66.3% vs. 71.1%). That
ounds like a “win” for PCI. The authors concluded,
owever, that PCI was inferior to CABG because repeat
evascularization—the driving force in the composite pri-
ary end point—occurred more frequently among PCI
atients than CABG patients (14% vs. 5.9%). What would
nowledgeable patients conclude? Does an 8% reduction in
epeat revascularization outweigh the increased pain and
ecovery time of CABG, and the higher risk of perioperative
omplications?
*Editorials published in the Journal of the American College of Cardiology reflect the
views of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology. The authors have reported that they have no
elationships to disclose.oFrom the Cardiovascular Division, University of Minnesota, Minneapolis, Minnesota.short history of left main revascularization: a story of risk.
ince its inception in 1960, CABG has been the gold
tandard for coronary revascularization. Compared with
edical therapy alone, CABG lessens both symptoms and
ortality in patients with significant stenosis of the LMCA.
edical therapy for patients with LMCA stenosis is abys-
al, with a 50% survival at 7 years (2). Conversely,
andomized trials consistently show CABG markedly im-
roves survival compared with medical therapy alone. The
ain, cost, and recuperation time of CABG were far
utweighed by the reduction of risk and improvement of
ymptoms.
Because it is less painful, less invasive, and has a very short
ecovery time, PCI has displaced CABG as the primary
ethod for coronary revascularization in patients who have
relatively low inherent risk of infarction and death. In
hese lower-risk groups (1- or 2-vessel disease, nondiabetic,
reserved left ventricular function), early comparative trials
f PCI and CABG consistently showed that both tech-
iques lead to similar survival and risk of myocardial
nfarction (MI), but patients undergoing PCI had more
epeat procedures and less angina relief over the long term
3). Patients weighed the outcomes and flocked to PCI
ecause it was less invasive.
As PCI methods improved, its reach extended to more
omplex coronary disease. The risk of dissection and abrupt
losure associated with balloon angioplasty limited its use to
airly limited, discrete coronary lesions. The introduction of
are-metal stents (BMS) reduced periprocedural disasters
coronary occlusion due to dissection) but only modestly
educed the risk of restenosis. This improvement in peripro-
edural complications led to attempts to treat LMCA
esions with BMS. Among lower-risk patients, bare-metal
tenting was associated with lower in-hospital morbidity,
ut still exposed the individual to a higher risk of unaccept-
ble restenosis and revascularization. Trials in high-risk
atients with LMCA disease were met with an unacceptable
3.7% in-hospital mortality and a 24.2% 1-year mortality
4). At this point in PCI history, the higher risk of PCI
utweighed the pain and prolonged recovery of CABG.
onsequently, PCI was generally reserved for patients with
n unacceptable surgical risk even though it was less
nvasive.
The development of drug-eluting stents (DES) and
dvances in bifurcation stenting during the past decade
mproved both immediate and long-term outcome of
MCA stenting. Six- to 12-month target vessel revascular-
zation (TVR) rates have ranged from 2% to 19% with DES
s opposed to 12% to 31% with BMS (5–7). Yet, concerns
emain regarding stent thrombosis, particularly when the
tent is incompletely apposed to the vessel wall, or dual
ntiplatelet therapy is not provided. A significant risk of
atastrophic left main thrombosis with DES would not
utweigh the pain and prolonged recovery of CABG.
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of outcomes. Every treatment has a myriad of potential
complications and also a number of positive effects. To gain
statistical advantage, we often combine end points. The
problem is that the individual end points usually have
significantly different impacts. The higher frequency of less
important outcomes often overshadows the really critical
outcomes, leading to false comparisons. The primary end
point of the trial by Boudriot et al. (1) was driven by the
increased revascularization rate in the PCI arm. Is repeat
PCI important enough to be included with death and MI as
a primary outcome parameter, or should each outcome be
weighted?
A health economist would present the composite end
point to a patient in practical terms. Recognizing the fact
that a patient values survival, morbidity, and discomfort
with differing levels of importance, he or she would
determine the relative value of the individual end points
for a patient using a “standard gamble” or “time-tradeoff”
technique. In the process of assigning various weights
(Table 1), the relative value of a stroke, MI, and death
could be compared on the same scale. We are not sure
what the correct weights are for each aspect of outcome,
but considering the relative importance of each would
help physicians and patients better assess the results of
treatment options.
The evidence to date. Like the excellent randomized trial
by Boudroit et al. (1), observational registries comparing
DES with CABG among patients with LMCA disease
have shown similar mortality but an excess number of
periprocedural MIs following CABG. A recent meta-
analysis including 1,278 patients receiving DES for LM
disease (median follow-up of 10 months) found a mortality
of 5.5%, TVR rate of 6.5%, and a major adverse cardiovas-
Comparison of Weighted to Unweighted End Points*Table 1 Comparison of Weighted to Unweighted End Points*
Complication Weight
Death 10
Stroke 5
Periprocedural MI 1
Acute renal failure 1
Re-revascularization 3
Perioperative atrial fibrillation 1
Neuropathy/tetraplegia 5
Redo sternotomy 2
Infection 2
CABG for initial failure 5
Total for all end points
Total for primary end points
*As observed by Boudroit et al. (1). Here, we use arbitrary weighting based on the value set of the
CABG) appears to be favorable compared to percutaneous coronary intervention (PCI). Using weig
f all of the reported complications, PCI appears to be highly favorable compared to CABG.
MI  myocardial infarction.cular event (MACE) rate of 16.5%. DES, in comparison toCABG, reduced the composite of stroke and MACE by
54% (odds ratio: 0.46 [95% confidence interval: 0.24 to
0.90]).
LeMANS (Left Main Angiographic Substudy) (n  104),
he first randomized trial comparing DES with CABG, found
o significant difference between the 2 arms in regard to death,
I, or stroke (8). A subgroup analysis of patients with LMCA
isease (n  705) from the SYNTAX (Synergy Between PCI
ith Taxus and Cardiac Surgery) trial found no significant
ifference in the composite of death, MI, stroke of repeat
evascularization (PCI arm 15.8% vs. CABG arm 13.7%,
 0.44) (9). Repeat revascularization occurred more
requently among PCI patients (11.8% vs. 6.5%, p  0.02).
mong patients with coexistent disease involving the
MCA and 2 vessels or 3 vessels, however, the pendulum
wung in favor of CABG.
The expansion of PCI into more complex LMCA
esion subsets will require additional randomized clinical
rials, and they are underway (EXCEL [Evaluation of
ience Prime versus Coronary Artery Bypass Surgery for
ffectiveness of Left Main Revascularization] and PRE-
OMBAT [Bypass Surgery Versus Angioplasty Using
irolimus-Eluting Stent in Patients With Left Main
oronary Artery Disease] trials). If the results of the
resent study are confirmed, then the scale may ulti-
ately tip to PCI for selected patients with unprotected
MCA disease. All outcomes are not created equal. We
eed to start using the established decision-making tools
o help us understand what is best for patients.
Reprint requests and correspondence: Dr. Robert F. Wilson,
Department of Medicine, University of Minnesota, MMC 508,
420 Delaware Street SE, Minneapolis, Minnesota 55455. E-mail:
Raw Occurrence Weighted Value
PCI CABG PCI
2 50 20
0 10 0
3 3 3
1 1 1
14 18 42
3 19 3
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s. Using the raw occurrences of the primary composite end point, coronary artery bypass grafting
lue events occurrences, however, CABG appears to be less favorable. Adding the weighted valueCABG
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